Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer
Emory University
Emory University
City of Hope Medical Center
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Mayo Clinic
NRG Oncology
M.D. Anderson Cancer Center
NRG Oncology
NRG Oncology
Peking Union Medical College
Uganda Cancer Institute
Sahlgrenska University Hospital
Ohio State University Comprehensive Cancer Center
Roswell Park Cancer Institute
City of Hope Medical Center
Ohio State University Comprehensive Cancer Center
Jiangsu Cancer Institute & Hospital
Centre Antoine Lacassagne
Mayo Clinic
City of Hope Medical Center
Mayo Clinic
M.D. Anderson Cancer Center
Jonsson Comprehensive Cancer Center
University of Michigan Rogel Cancer Center
Shanghai Junshi Bioscience Co., Ltd.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Shanghai Pulmonary Hospital, Shanghai, China
University Hospital, Antwerp
Eye & ENT Hospital of Fudan University
RenJi Hospital
Hebei Medical University Fourth Hospital
Fourth Affiliated Hospital of Guangxi Medical University